Form 4: Lantheus Holdings President Paul Blanchfield Reports Stock Transactions

Paul Blanchfield, President of Lantheus Holdings, reports the acquisition and disposal of company stock and stock options.

Summary

• On March 5, 2025, Paul Blanchfield, President of Lantheus Holdings, reported transactions involving the company's stock.
• He sold 2,084 shares of common stock at $98 per share under a pre-arranged Rule 10b5-1 trading plan.
• Blanchfield also acquired 26,871 shares of common stock, consisting of restricted stock units (RSUs) and performance-based restricted stock units (PSUs).
• He was also granted options to purchase 15,668 shares of common stock at an exercise price of $100.48, vesting in three equal annual installments starting March 5, 2026.
• Following these transactions, Blanchfield directly owns 118,699 shares of common stock and options to purchase 15,668 shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The transactions are part of a pre-planned trading strategy and standard compensation practices. There is no indication of unusual or concerning activity.

Positives

• The granting of stock options and restricted stock units to the President aligns his interests with those of the shareholders.
• The vesting schedule of the options and RSUs encourages long-term commitment from the executive.
• The use of performance-based restricted stock units (PSUs) incentivizes the achievement of specific performance goals.

Risks

• The ultimate value of the PSUs is dependent on the company's performance over the next three years, which is subject to various market and operational risks.
• The executive could leave the company before the options and RSUs fully vest, potentially forfeiting some of the granted equity.

Future Outlook

The document does not contain specific forward-looking statements about the company's future performance, but the vesting of RSUs, PSUs, and stock options is tied to future performance and continued employment.

Industry Context

Insider transactions are routinely monitored by investors to gauge management's sentiment about the company's prospects. The sale of shares under a pre-arranged plan is common, while the acquisition of shares through equity grants is a standard component of executive compensation packages.

Comparison to Industry Standards

• Equity compensation practices vary across the pharmaceutical and biotechnology industries.
• Companies like GE Healthcare, Siemens Healthineers, and Philips Healthcare also utilize a mix of stock options, RSUs, and PSUs to incentivize their executives.
• The vesting schedules and performance metrics associated with these grants are typically aligned with industry benchmarks for long-term value creation.

Stakeholder Impact

• The transactions have a minor impact on shareholders, as the sale of shares by the President is relatively small.
• The equity grants incentivize the President to focus on long-term value creation for shareholders.
• Employees may be indirectly affected by the performance-based component of the PSUs, as the company's overall performance impacts the payout.

Key Dates